In the last trading session, 1.55 million shares of the Neogenomics Inc (NASDAQ:NEO) were traded, and its beta was 1.64. Most recently the company’s share price was $7.41, and it changed around $0.13 or 1.79% from the last close, which brings the market valuation of the company to $953.63M. NEO currently trades at a discount to its 52-week high of $19.11, offering almost -157.89% off that amount. The share price’s 52-week low was $6.08, which indicates that the current value has risen by an impressive 17.95% since then.
Neogenomics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.88. If we narrow it down even further, the data shows that 0 out of 15 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 6 recommended NEO as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. Neogenomics Inc is expected to report earnings per share of 0.03 for the current quarter.
Neogenomics Inc (NASDAQ:NEO) trade information
Instantly NEO has showed a green trend with a performance of 1.79% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 8.23 on recent trading dayincreased the stock’s daily price by 9.96%. The company’s shares are currently down -55.04% year-to-date, but still down -8.63% over the last five days. On the other hand, Neogenomics Inc (NASDAQ:NEO) is -26.56% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $15, which translates to bulls needing to increase their stock price by 50.6% from its current value. Analyst projections state that NEO is forecast to be at a low of $12 and a high of $18.
Neogenomics Inc (NEO) estimates and forecasts
The year-over-year growth rate is expected to be 12.75%, up from the previous year.
Consensus estimates provided by 14 financial analysts predict the company will bring in an average of 182.91M in revenue for the current quarter. 14 analysts expect Neogenomics Inc to make 192.49M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 164.5M and 167.82M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 11.19%. Forecasts for the next quarter put sales growth at 14.70%.
Neogenomics Inc earnings are expected to increase by 38.64% in 2025, but the outlook is positive 66.25% per year for the next five years.
NEO Dividends
Neogenomics Inc’s next quarterly earnings report is expected to be released in June.
VANGUARD GROUP INC, with 11.1716% or 14.12 million shares worth $195.87 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Apr 30, 2025 . The former held 7.8 shares worth $57.76 million, making up 6.06% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 3.95 shares worth around $29.28 million, which represents about 3.07% of the total shares outstanding.
